Amyloid pathology and axonal injury after brain trauma

ABSTRACT

Objective: To image β-amyloid (Aβ) plaque burden in long-term survivors of traumatic brain injury (TBI), test whether traumatic axonal injury and Aβ are correlated, and compare the spatial distribution of Aβ to Alzheimer disease (AD).

Methods: Patients 11 months to 17 years after moderate–severe TBI underwent 11C-Pittsburgh compound B (11C-PiB)-PET, structural and diffusion MRI, and neuropsychological examination. Healthy aged controls and patients with AD underwent PET and structural MRI. Binding potential (BPND) images of 11C-PiB, which index Aβ plaque density, were computed using an automatic reference region extraction procedure. Voxelwise and regional differences in BPND were assessed. In TBI, a measure of white matter integrity, fractional anisotropy, was estimated and correlated with 11C-PiB BPND.

Results: Twenty-eight participants (9 with TBI, 9 controls, 10 with AD) were assessed. Increased 11C-PiB BPND was found in TBI vs controls in the posterior cingulate cortex and cerebellum. Binding in the posterior cingulate cortex increased with decreasing fractional anisotropy of associated white matter tracts and increased with time since injury. Compared to AD, binding after TBI was lower in neocortical regions but increased in the cerebellum.

Conclusions: Increased Aβ burden was observed in TBI. The distribution overlaps with, but is distinct from, that of AD. This suggests a mechanistic link between TBI and the development of neuropathologic features of dementia, which may relate to axonal damage produced by the injury.

Neurology® 2016;86:1-8

GLOSSARY

Aβ = β-amyloid; AD = Alzheimer disease; ANOVA = analysis of variance; BPND = nondisplaceable binding potential; 11C-PiB = 11C-Pittsburgh compound B; DTI = diffusion tensor imaging; FA = fractional anisotropy; GM = gray matter; MNI = Montreal Neurological Institute; PCC = posterior cingulate cortex; ROI = region of interest; TAI = traumatic axonal injury; TBI = traumatic brain injury; TBSS = tract-based spatial statistics; WM = white matter.

Traumatic brain injury (TBI) is the leading cause of disability in young adults. Survivors may deteriorate clinically many years after injury, and TBI is thought to be a major risk factor for dementia. However, the mechanisms relating acute injury to later neurodegeneration are unclear, and the prevalence of distinct types of dementia such as Alzheimer disease (AD) and chronic traumatic encephalopathy is uncertain.

A mechanistic link between moderate to severe TBI and AD is suggested by the observation that β-amyloid (Aβ) aggregates are found in brains of up to a third of patients who die acutely after TBI, and in a similar proportion who survive for a year or more. Traumatic axonal injury (TAI), a pathology consistently observed after TBI, offers a potential mechanism for Aβ genesis. It is postulated that abundant amyloid precursor protein, which accumulates in damaged axons, is aberrantly cleaved to form Aβ, which subsequently aggregates as Aβ plaques.

From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology & Neuroscience (P.H., M.V., F.E.T.), King’s College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the Wellcome Trust.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2016 American Academy of Neurology
Immunohistochemical evidence also shows that the enzymes necessary for Aβ cleavage accumulate at sites of TAI.5

Localization of fibrillar Aβ pathology in vivo is possible using PET. The amyloid tracer 11C-Pittsburgh compound B (11C-PiB) shows robust retention in brains of patients with AD7 in a pattern that corresponds with neuropathologic studies of Aβ plaque distribution, with increases initially in the precuneus/posterior cingulate cortex (PCC), frontal cortex, and caudate nuclei, then lateral temporal and parietal cortex.8,9 Recently, a pilot 11C-PiB-PET study in patients with moderate to severe TBI less than 1 year after injury found increased uptake in cortical gray matter (GM) and striatum.10 These findings suggest that Aβ imaging in the chronic phase after TBI may inform our understanding of neurodegeneration in long-term survivors of TBI.

Diffusion tensor imaging (DTI) can be used to estimate in vivo the degree of axonal injury following TBI.11–14 In this study, we combined 11C-PiB-PET and DTI to test the following hypotheses: (1) Aβ pathology is present in long-term survivors of TBI without dementia; and (2) Aβ pathology after moderate to severe TBI is related to the amount and distribution of TAI.

**METHODS** Study design and participants. In this cross-sectional study, 9 patients with a history of a single moderate–severe TBI based on Mayo criteria15 were assessed with 11C-PiB-PET, structural T1 MRI, DTI, and neuropsychological examination. Patients were recruited at least 11 months after their injury (e-Methods on the Neurology® Web site at Neurology.org). For comparison of 11C-PiB binding, a group of patients with AD had 11C-PiB-PET and structural MRI (e-Methods). We used 3 healthy control groups: (1) for comparison of 11C-PiB binding, a group of healthy aged controls had PiB-PET and structural MRI; (2) for comparison of neuropsychological performance, a second group of healthy aged controls had PiB-PET and structural MRI; and (3) for comparison of healthy aged controls underwent structural MRI and DTI.

Standard protocol approvals, registrations, and patient consents. The project was approved by Hammersmith and Queen Charlotte’s and Chelsea Research Ethics Committee. All participants gave written informed consent.

Procedures. A neuropsychological test battery was performed on patients with TBI and age-matched controls (e-Methods). Patients with AD and healthy aged controls underwent the Mini-Mental State Examination.

An overview of the imaging methods is shown in figure e-1. All patients and healthy aged controls had 11C-PiB-PET using a Siemens ECAT EXACT HR+ scanner (Siemens Medical Systems, Erlangen, Germany). 11C-PiB was manufactured and supplied by Hammersmith Imanet (London, UK). All participants had an IV bolus injection of 11C-PiB, mean dose 370 MBq, and dynamic PET emission scans were acquired over 90 minutes.

To generate nondisplaceable binding potential (BPND) images of 11C-PiB, we used a supervised clustering procedure for automatic reference region extraction.16 T1 images were automatically segmented into GM and WM. The tissue segmentations were warped to an average group template image using a diffeomorphic nonlinear image registration procedure (DARTEL).17 The group template image was then registered to Montreal Neurological Institute (MNI) space. Each individual’s 11C-PiB BPND image was coregistered to their T1 image, then the individual flow-fields and template registration obtained from the DARTEL procedure were used to warp the BPND images to MNI space. The normalized BPND images were masked using the thresholded GM template and smoothed (8 mm full width at half maximum) (e-Methods).

11C-PiB binding potentials were also sampled from anatomically defined regions of interest (ROIs). The MAPER (multi-atlas propagation with enhanced registration) procedure was used to generate native-space ROIs.18 To improve sampling accuracy, ROI masks were intersected with thresholded tissue probability maps (e-Methods). To confirm that the hippocampal ROI results were not an effect of mislabeling due to atrophy, sampling was repeated on hippocampal masks that were manually segmented using a harmonized protocol.19

In patients with focal injuries, lesions apparent on T1 imaging were manually segmented and excluded from ROIs and voxelwise analyses. We also investigated 11C-PiB binding within a lesion, the lesion penumbra, and normal-appearing GM in the same hemisphere (e-Methods).

Patients with TBI and a group of healthy aged-matched controls underwent DTI (e-Methods). Voxelwise maps of fractional anisotropy (FA), a measure of WM tract integrity after TBI, were calculated using the FSL Diffusion Toolkit.20 The FA maps were skeletonized using tract-based spatial statistics (TBSS).21 We calculated the mean FA of the TBSS skeleton and also of selected tracts from the Johns Hopkins University WM Tractography Atlas.22 We chose tracts connected to GM regions that had shown increased 11C-PiB binding in TBI. We also sampled the corticospinal tract as a control, since this was not connected to these regions.

**RESULTS** Nine patients with TBI (mean age 44.1 ± 4.9 years, range 38–54) were recruited 11 months to 17 years after injury (table 1). Ten patients with AD...
(mean age 67.3 ± 4.5, range 58–76) and 9 healthy aged controls (62.3 ± 4.3, range 55–66) were also assessed. In addition, a group of 15 age-matched controls (37.3 ± 11.3, range 19–60) underwent neuropsychological assessment and a separate group of 11 age-matched controls (40.9 ± 5.4, range 35–51) underwent MRI and DTI. None of the patients had a clinical diagnosis of posttraumatic stress disorder or anxiety disorder. One patient had a diagnosis of depression following the TBI. Structural T1 scans were reviewed by a senior neuroradiologist. Four patients with TBI had no abnormalities. The remaining 5 had focal lesions, with damage in the frontal (n = 3) or temporal (n = 3) lobes (figure e-2). One patient had undergone a parietotemporal lobectomy following TBI.

### Neuropsychological impairment after TBI

The patients with TBI showed impairments in neuropsychological performance compared to age-matched healthy controls. Significantly poorer responses were seen across a range of tasks, including tests of attention, information processing speed, and cognitive flexibility (table e-1). In other tests, the patients were well matched with controls. As expected, the AD group had a lower Mini-Mental State Examination score (mean 21.1/30 ± 4.1) than healthy aged controls (all 30/30, t = −6.54, df = 9, p < 0.001).

### Amyloid pathology after TBI is detected by ¹¹C-PiB binding

¹¹C-PiB BPND images of the TBI group are shown for individual patients (figure 1). Slices from a representative patient with AD and a healthy aged control are also presented (figure 1).

### Table 1  Demographics and clinical data of all patients with traumatic brain injury

<table>
<thead>
<tr>
<th>Age, y</th>
<th>Sex</th>
<th>Education level</th>
<th>Etiology</th>
<th>Lowest GCS</th>
<th>PTA, h</th>
<th>Medication</th>
<th>Time since trauma, mo</th>
<th>Focal lesion(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>M</td>
<td>Postgraduate</td>
<td>Unknown</td>
<td>4</td>
<td>24</td>
<td>Gabapentin, modafinil, amitriptyline</td>
<td>76</td>
<td>Yes</td>
</tr>
<tr>
<td>55</td>
<td>M</td>
<td>Postgraduate</td>
<td>Fall</td>
<td>4</td>
<td>Unknown</td>
<td>Nil</td>
<td>28</td>
<td>Yes</td>
</tr>
<tr>
<td>42</td>
<td>M</td>
<td>School to 18 y</td>
<td>Pedestrian hit by a car</td>
<td>4</td>
<td>432</td>
<td>Nil</td>
<td>72</td>
<td>No</td>
</tr>
<tr>
<td>42</td>
<td>M</td>
<td>School to 16 y</td>
<td>Motorcycle accident</td>
<td>4</td>
<td>UK</td>
<td>Trospium chloride, folic acid</td>
<td>198</td>
<td>Yes</td>
</tr>
<tr>
<td>40</td>
<td>M</td>
<td>Graduate</td>
<td>Motorcycle accident</td>
<td>4</td>
<td>1,008</td>
<td>Nil</td>
<td>125</td>
<td>Yes</td>
</tr>
<tr>
<td>42</td>
<td>F</td>
<td>Postgraduate</td>
<td>Pedestrian hit by a car</td>
<td>3</td>
<td>144</td>
<td>Codeine paracetamol</td>
<td>76</td>
<td>Yes</td>
</tr>
<tr>
<td>45</td>
<td>M</td>
<td>School to 16 y</td>
<td>Assault</td>
<td>4</td>
<td>5,040</td>
<td>Thiamine</td>
<td>11</td>
<td>No</td>
</tr>
<tr>
<td>49</td>
<td>M</td>
<td>School to 18 y</td>
<td>Probable assault</td>
<td>4</td>
<td>2</td>
<td>Nil</td>
<td>11</td>
<td>No</td>
</tr>
<tr>
<td>38</td>
<td>M</td>
<td>Graduate</td>
<td>Motorcycle accident</td>
<td>6</td>
<td>Unknown</td>
<td>Citalopram, modafinil, omeprazole</td>
<td>106</td>
<td>No</td>
</tr>
</tbody>
</table>

Abbreviations: GCS = Glasgow Coma Scale; PTA = posttraumatic amnesia.

**Figure 1 ¹¹C-PiB binding following TBI**

Images of axial T1 MRI are superimposed with ¹¹C-PiB BPND maps for all patients with TBI and a representative healthy aged control and a participant with AD. For patients with TBI, the interval in months from the time of TBI to PET scanning and the age in years of each participant at scanning is also shown. AD = Alzheimer disease; BPND = nondisplaceable binding potential; ¹¹C-PiB = ¹¹C-Pittsburgh compound B; TBI = traumatic brain injury.
Figure 2 Increased $^{11}$C-PiB binding in TBI and AD

(A) Blue-light blue areas showed significantly increased $^{11}$C-PiB BP$_{ND}$ in TBI compared to healthy aged controls. (B) Red-yellow areas showed significantly increased binding in AD compared to controls. (C) Blue-light blue areas showed significantly increased $^{11}$C-PiB BP$_{ND}$ in TBI compared to AD. Red-yellow areas showed significantly increased binding in AD compared to TBI. Images are shown thresholded at $p < 0.001$ uncorrected. AD = Alzheimer disease; BP$_{ND}$ = nondisplaceable binding potential; $^{11}$C-PiB = $^{11}$C-Pittsburgh compound B; TBI = traumatic brain injury.

$^{11}$C-PiB binding is decreased around focal lesions. Visual inspection of individual TBI BP$_{ND}$ images showed no binding in the vicinity of focal cortical lesions evident on structural MRI. To confirm this, we sampled binding in ROIs placed in and around the most prominent lesion in each brain. As expected, there was no specific binding in the focal lesion. In addition, binding in the penumbra was reduced compared to normal-appearing GM in the same hemisphere ($t = -11.54$, $df = 4$, $p < 0.001$).

$^{11}$C-PiB binding after TBI is correlated with WM damage and time since injury. We next examined whether Aβ plaque pathology in the PCC was associated with the degree of TAI in the patients with TBI. We tested the hypothesis that regional GM $^{11}$C-PiB binding increases with lower FA (indicative of axonal injury) in the cingulum bundles that were directly connected to the PCC (figure 4A). Mean FA in all tracts examined was reduced as expected (figure 4B). PCC BP$_{ND}$ was negatively correlated in both the left cingulum ($R = -0.733, p = 0.031$) and right cingulum ($R = -0.750, p = 0.025$, figure 4C), a relationship that survived correction for the age of the patient ($R = -0.758, p = 0.029$; $R = -0.787, p = 0.020$). The mean FA of the WM skeleton also showed a correlation with PCC binding ($R = -0.733, p = 0.031$), although this was only of borderline significance when correcting for age ($R = -0.694, p = 0.056$). There was no significant correlation found with the corticospinal tract FA. $^{11}$C-PiB binding in the PCC also increased with time since injury duration ($R = 0.767, p = 0.021$), although this was not significant after correcting for age ($R = 0.625, p = 0.097$). Of the 4 FA measures, the mean FA of the left cingulum also correlated with time since injury ($R = -0.717, p = 0.037$). There was no independent relationship between $^{11}$C-PiB binding and FA after correction for time since injury. There was also no correlation between patient age and $^{11}$C-PiB binding or FA.

$^{11}$C-PiB binding is not correlated with neuropsychological impairment in TBI. There were no significant correlations between PCC binding and behavioral performance in the patients with TBI.

Distinct distributions of $^{11}$C-PiB binding in TBI and AD. The direct contrast of AD and controls showed increased $^{11}$C-PiB binding in AD association cortex and cingulate (figure 2B). Conjunction analysis showed that $^{11}$C-PiB binding was increased in a cluster within the precuneus/PCC in both AD and TBI compared to controls. In general, $^{11}$C-PiB binding was higher in AD than TBI across regions, but the TBI cases had relatively increased binding in the cerebellum (figure 2C). Interrogating ROI data with ANOVA confirmed the voxel-level findings. Increased $^{11}$C-PiB binding was seen in cortical association and cingulate regions in AD whereas increased cerebellar binding was seen in TBI (e-Results). There was no correlation between patient age and regional $^{11}$C-PiB binding within any of the 3 participant groups.
DISCUSSION  TBI can predispose patients to various types of dementia, but there is no consensus about how post-TBI dementia syndromes should be classified or diagnosed. Patients often clinically deteriorate years after TBI, but it is difficult to determine whether this is related to the prior head injury. Improved methods of characterizing neurodegenerative processes triggered by TBI are needed. We investigated amyloid pathology using $^{11}$C-PiB-PET. For the first time, we show in vivo that increases in $^{11}$C-PiB binding are present in long-term survivors of TBI in a distribution overlapping with AD but also involving the cerebellum. A mechanistic link between axonal injury and amyloid pathology is suggested by the relationship between cortical $^{11}$C-PiB binding and WM damage in connected tracts.

In AD, Aβ deposition usually begins in inferior frontal and cingulate association cortex, extending into other association cortical regions. Early deposition is seen in the PCC, and we observed increased $^{11}$C-PiB uptake in both patients with TBI and those with AD. While the ventromedial frontal cortex is affected early in AD, the hippocampus and cerebellum are not usually involved until much later in the disease. In keeping with this pattern, we observed strong $^{11}$C-PiB binding in the prefrontal cortex in our patients with AD, but relatively low levels in the hippocampus and cerebellum. However, a different pattern was observed in our patients with TBI, who had increased cerebellar $^{11}$C-PiB binding relative to both AD and controls. The distinct distribution of $^{11}$C-PiB binding in the 2 contexts suggests that amyloid pathology is triggered by a different mechanism after TBI, which is likely to relate to biomechanical forces underlying the distinctive pattern of Aβ plaque pathology seen in cases of chronic traumatic encephalopathy. TBI might also accelerate an aging process and our results may reflect this change in aging trajectory, particularly considering that the increased $^{11}$C-PiB binding after TBI was observed in comparison to a much older aged control group. However, in keeping with studies of AD, $^{11}$C-PiB binding did not correlate with cognitive impairment.

Axonal damage produced at the time of injury may act as an initial trigger for Aβ production and accumulation of amyloid pathology. In keeping with this possibility, we observed an association between the extent of WM damage and $^{11}$C-PiB binding in the PCC following TBI. The biomechanical effects of torsional and shear stress on WM tracts produce TAI, and this is thought to be an important factor driving overproduction of Aβ, leading to its aggregation in the acute phase. Axons and their surrounding myelin are damaged, and the pathologic effects of injury remain visible for many years, particularly in long-distance WM tracts. Animal models and human autopsy studies provide evidence that Aβ
is produced at the site of axonal injury shortly after TBI.\(^6\)

The relationship between \(^{11}\)C-PiB binding and WM damage was seen in the cingulum bundles, which connect to the PCC. The relationship was not observed in the corticospinal tract, which is not directly connected to the PCC, suggesting a more specific link between the 2 observations. Misfolded proteins, including A\(_\beta\), have the capacity to move from neuron to neuron via prion-like transsynaptic spread,\(^{29,30}\) and computational simulations show that a simple diffusion mechanism can produce the complex patterns of brain atrophy observed in AD if large-scale WM structure is factored into the model.\(^31\) The implication for TBI is that the WM may be both a source of A\(_\beta\) and a conduit for A\(_\beta\) diffusion. The correlation between measures of TAI and A\(_\beta\) pathology in the PCC may reflect its role as a highly connected cortical hub,\(^32\) which integrates damage that spreads from damaged WM tracts. The time elapsed since a patient's injury also correlated with \(^{11}\)C-PiB binding, suggesting there is a progressive neurodegenerative process. Our results suggest that \(^{11}\)C-PiB binding, WM structure, age, and time since injury are interrelated, and longitudinal studies with larger numbers will be needed to clarify the causal relationships. Such studies should also examine \(^{11}\)C-PiB binding in the context of host genotype, particularly APOE,\(^33\) which was not addressed here.

Our findings are broadly consistent with a previous \(^{11}\)C-PiB study in patients with TBI scanned less than 1 year after injury (median 11 days). Hong et al.\(^10\) showed increased cortical and striatal \(^{11}\)C-PiB binding early after TBI. Of note, the validity of in vivo neuroimaging was supported by [\(^3\)H]PiB autoradiography and A\(_\beta\) immunohistochemistry. In contrast to our study, this earlier work used the cerebellum as a reference region for quantification of \(^{11}\)C-PiB binding, assuming that there was minimal A\(_\beta\) plaque density in the cerebellum and that the ratio of cortical to cerebellar binding provided a measure of cortical A\(_\beta\) burden.\(^34\) Hong et al. provide evidence to support this assumption early after TBI. However, our results demonstrate that this is not the case in the chronic phase after TBI. Our initial analyses in TBI using the cerebellum as a reference region suggested decreased cortical \(^{11}\)C-PiB binding. Therefore, we used a procedure for automatic reference region extraction that has been validated in familial AD and does not require a single anatomically defined reference region.\(^16\)

Our study has a number of potential limitations. First, given the small sample size, our findings should be regarded as preliminary. Second, the \(^{11}\)C-PiB healthy controls were age-matched to the AD group, and so were older than the TBI group. Although 2 separate age-matched control groups would have been
preferable. Aβ pathology increases with age and so a comparison with older healthy controls is likely to have reduced our sensitivity to detect a relative increase in the younger TBI group. Therefore, the presence of abnormalities in a relatively young TBI group is even more striking. Third, it is possible that GM tissue differences such as atrophy, associated with AD or aging, could have biased our group contrast results. A number of analysis steps were used to minimize this possibility: an advanced algorithm for optimized registration of brain images into standard space (DARTEL)36; 11C-PiB binding was only assessed in regions where the GM probability was high; and ROI analyses, based on both automated segmentations, were used to provide confirmatory results. To control for the possible effects of focal injury after TBI, we also excluded lesioned areas from the analysis. It is possible that the extent of focal lesions was underestimated as we used T1 imaging to segment the lesions. However, since 11C-PiB binding was reduced in visible lesions, this possibility would have biased the analysis against detecting increases in 11C-PiB.

We provide 11C-PiB-PET evidence for the presence of amyloid pathology many years after injury in patients with TBI without dementia. The distribution of 11C-PiB binding partially overlapped with that seen in typical AD but also affected the cerebellum, unlike in AD. This suggests a different mechanism for amyloid plaque genesis. Our findings support the hypothesis that amyloid plaque pathology is related to the presence of axonal damage produced subsequent to the TBI.

AUTHOR CONTRIBUTIONS
Dr. Scott performed the analysis and interpretation of the data and wrote the manuscript. Dr. Ramakrishnasign contributed to the study design and coordination, and acquisition of data. Dr. Edison revised the manuscript and contributed to the acquisition of data. Dr. Hellyer contributed to the analysis of the data and revised the manuscript. Dr. Cole contributed to the analysis of the data and revised the manuscript. Dr. Veronese contributed to the acquisition of the data. Dr. Leech contributed to the analysis of the data. Dr. Greenwood revised the manuscript and contributed to the acquisition of data. Prof. Turkheimer contributed to the analysis of the data and revisied the manuscript. Prof. Gentleman revised the manuscript. Prof. Heckemann contributed to the analysis of the data and revised the manuscript. Prof. Matthews revised the manuscript. Prof. Brooks revised the manuscript. Prof. Sharp contributed to the study concept, design and coordination, acquisition of data, supervision of the study, and wrote the manuscript.

ACKNOWLEDGMENT
The authors thank all the patients and controls who participated in this work.

STUDY FUNDING
No targeted funding reported.

DISCLOSURE
G. Scott was supported by a clinical research fellowship awarded in the Wellcome Trust–GlaxoSmithKline Translational Medicine Training Programme. This work was supported by the Imperial College Healthcare Trust Biomedical Research Centre. A. Ramlakhanishing, P. Edison, P. Hellyer, and J. Cole report no disclosures relevant to the manuscript. M. Veronese is supported by an MRC PET programme grant (G1100809/1). R. Leech and R. Greenwood report no disclosures relevant to the manuscript. F. Turkheimer is supported by an MRC PET programme grant (G1100809/1). S. Gentleman and R. Heckemann report no disclosures relevant to the manuscript. P. Matthews has consulted or received honoraria for lectures from GlaxoSmithKline, Biogen, IDEC, DIOCO, and Novartis, and has research support from the MS Society of Great Britain, the Progressive MS Alliance, the MRC, and GlaxoSmithKline, and personal support from the Edmond J. Safra Foundation and from Lily Safra. Matthews is an NIHR Senior Investigator. D. Brooks has been a consultant and part time employee for GE Healthcare in the past. D. Sharp receives personal and research support from the National Institute for Health Research and the Medical Research Council (UK). Go to Neurology.org for full disclosures.

Received April 17, 2015. Accepted in final form September 3, 2015.

REFERENCES